A cadre of venture investors speaking on a panel at this week’s INVEST conference in Chicago aren’t particularly concerned about the gyrations in the life sciences public markets. Venture capital remains fairly agnostic of the troughs and peaks of the stock market, and life sciences investment will likely continue on at a strong pace, they said – largely because of the quality of the science.
{iframe}http://medcitynews.com/2016/04/372147/?utm_source=MedCity+News+Subscribers&utm_campaign=360003a1cc-MCN+Daily+Email&utm_medium=email&utm_term=0_5092836c41-360003a1cc-408826397{/iframe}